Fidelity Investments’s Syndax Pharmaceuticals SNDX Stock Holding History

Fidelity Investments’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122K	Sell	5,574 -168,419	-97%	-$3.5M	﹤0.01%	3880
2026 Q1	$4.06M	Buy	173,993 +33,433	+24%	+$726K	﹤0.01%	2369
2025 Q4	$2.95M	Buy	140,560 +135,459	+2,656%	+$2.36M	﹤0.01%	2463
2025 Q3	$78.5K	Sell	5,101 -155,817	-97%	-$2.04M	﹤0.01%	3766
2025 Q2	$1.51M	Buy	160,918 +38,660	+32%	+$426K	﹤0.01%	2587
2025 Q1	$1.5M	Buy	122,258 +37,057	+43%	+$523K	﹤0.01%	2537
2024 Q4	$1.13M	Buy	85,201 +35,953	+73%	+$615K	﹤0.01%	2629
2024 Q3	$948K	Buy	49,248 +12,377	+34%	+$256K	﹤0.01%	2616
2024 Q2	$757K	Buy	36,871 +2,801	+8%	+$58.6K	﹤0.01%	2604
2024 Q1	$811K	Sell	34,070 -6,626	-16%	-$148K	﹤0.01%	2571
2023 Q4	$879K	Sell	40,696 -3,286	-7%	-$50.5K	﹤0.01%	2510
2023 Q3	$639K	Buy	43,982 +2,237	+5%	+$42.3K	﹤0.01%	2570
2023 Q2	$874K	Buy	41,745 +204	+0.5%	+$4.25K	﹤0.01%	2505
2023 Q1	$877K	Buy	41,541 +317	+0.8%	+$7.88K	﹤0.01%	2549
2022 Q4	$1.05M	Sell	41,224 -124,649	-75%	-$2.91M	﹤0.01%	2528
2022 Q3	$3.99M	Buy	165,873 +40,217	+32%	+$902K	﹤0.01%	2237
2022 Q2	$2.42M	Sell	125,656 -63,087	-33%	-$1.05M	﹤0.01%	2447
2022 Q1	$3.28M	Buy	188,743 +1,394	+0.7%	+$23.5K	﹤0.01%	2475
2021 Q4	$4.1M	Buy	+187,349	New	+$3.46M	﹤0.01%	2409
2018 Q4	–	Sell	-348,653	Closed	-$2.82M	–	4099
2018 Q3	$2.82M	Sell	348,653 -211,549	-38%	-$1.51M	﹤0.01%	2297
2018 Q2	$3.93M	Hold	560,202	–	–	﹤0.01%	2206
2018 Q1	$7.97M	Sell	560,202 -142,642	-20%	-$1.51M	﹤0.01%	2019
2017 Q4	$6.16M	Sell	702,844 -394,707	-36%	-$3.91M	﹤0.01%	2108
2017 Q3	$12.8M	Sell	1,097,551 -244,093	-18%	-$2.99M	﹤0.01%	1856
2017 Q2	$18.7M	Buy	1,341,644 +91,328	+7%	+$1.04M	﹤0.01%	1701
2017 Q1	$17.2M	Sell	1,250,316 -229,731	-16%	-$2.39M	﹤0.01%	1751
2016 Q4	$10.6M	Sell	1,480,047 -614,417	-29%	-$6.73M	﹤0.01%	1946
2016 Q3	$31.8M	Hold	2,094,464	–	–	﹤0.01%	1484
2016 Q2	$20.6M	Hold	2,094,464	–	–	﹤0.01%	1665
2016 Q1	$27.9M	Buy	+2,094,464	New	+$26.3M	﹤0.01%	1507

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Fidelity Investments's SNDX Position: Q2 2026 in Review

Fidelity Investments reduced its Syndax Pharmaceuticals (SNDX) stake by 97% in Q2 2026, selling an estimated $3.5M and leaving 5,574 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #3880.

Fidelity Investments first reported a position in SNDX in Q1 2016 and has held it in 30 quarters since. The position peaked at $31.8M in Q3 2016. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Fidelity Investments held 5,574 shares of Syndax Pharmaceuticals worth $122K as of Q2 2026.
Fidelity Investments sold 168,419 Syndax Pharmaceuticals shares in Q2 2026, an estimated $3.5M.
Syndax Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3880 holding.
Fidelity Investments first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 30 quarters since.
Fidelity Investments's Syndax Pharmaceuticals position peaked at $31.8M in Q3 2016.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.